ArticleBMC endocrine disorders2026
Effect of short-term tirzepatide treatment on mean platelet volume in patients with obesity: a retrospective controlled study.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveObesity is associated with chronic low-grade inflammation, increased cardiovascular risk, and alterations in platelet indices [1-5]. Mean platelet volume (MPV) is an easily obtainable surrogate marker that has been linked to platelet activation and inflammatory burden [4, 6-8]. This study evaluated whether short-term tirzepatide therapy was associated with changes in MPV in patients with obesity compared with an untreated control group.
methodsIn this retrospective controlled study, 60 adults with obesity were included: 30 patients who received tirzepatide for two months and 30 untreated controls followed during the same period. Demographic data, body mass index (BMI), and MPV values at baseline and at two months were obtained from electronic medical records. Within-group changes were assessed using paired tests. Between-group comparisons of change scores were performed, and multivariable linear regression was used to evaluate the association between tirzepatide treatment and MPV change after adjustment for baseline BMI, baseline MPV, age, and sex.
resultsBaseline BMI and MPV were comparable between the tirzepatide and control groups (BMI: 40.22 ± 4.10 vs. 39.86 ± 3.49 kg/m², p = 0.713; MPV: 10.65 ± 0.87 vs. 10.18 ± 1.30 fL, p = 0.105). In the tirzepatide group, BMI decreased significantly from 40.22 ± 4.10 to 36.30 ± 3.90 kg/m² (mean change - 3.92 kg/m², 95% CI -5.93 to -1.91; p < 0.001), and MPV decreased from 10.65 ± 0.87 to 9.72 ± 1.17 fL (mean change - 0.94 fL, 95% CI -1.44 to -0.44; p < 0.001). The between-group difference in MPV change was significant (mean difference - 1.35 fL, 95% CI -2.22 to -0.48; p = 0.003). In adjusted regression, tirzepatide treatment remained independently associated with greater MPV reduction (beta - 1.13, 95% CI -1.97 to -0.29; p = 0.009).
conclusionShort-term tirzepatide treatment was associated with significant reductions in BMI and MPV compared with untreated controls. Because of the retrospective design, short follow-up, and absence of direct inflammatory and platelet-function biomarkers, these findings should be interpreted as hypothesis-generating rather than conclusive evidence of a direct platelet-modulating effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.